CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages 590-598

  Seto, Takashi ^a   Kiura, Katsuyuki ^b   Nishio, Makoto ^c   Nakagawa, Kazuhiko ^d   Maemondo, Makoto ^e   Inoue, Akira ^f   Hida, Toyoaki ^g   Yamamoto, Nobuyuki ^h   Yoshioka, Hiroshige ⁱ   Harada, Masao ^j   Ohe, Yuichiro ^k   Nogami, Naoyuki ^l   Takeuchi, Kengo ^m   Shimada, Tadashi ⁿ   Tanaka, Tomohiro ⁿ   Tamura, Tomohide ^o  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Miyagi Cancer Center   (Japan)

^f TOHOKU UNIVERSITY HOSPITAL   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ KURASHIKI CENTRAL HOSPITAL   (Japan)

^j HOKKAIDO CANCER CENTER   (Japan)

^k NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^m CANCER INSTITUTE   (Japan)

ⁿ CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^o NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CH 5424802; PROTEIN TYROSINE KINASE INHIBITOR; RO 5424802; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC PNEUMONITIS; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BRAIN EDEMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG WITHDRAWAL; DYSGEUSIA; EVENING DOSAGE; FEMALE; GENE; GENE REARRANGEMENT; HUMAN; HYPOPHOSPHATEMIA; INTERSTITIAL LUNG DISEASE; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIUS FRACTURE; RECOMMENDED DRUG DOSE; SCLEROSING CHOLANGITIS; SIDE EFFECT; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR BLEEDING; TUMOR REGRESSION; VISUAL IMPAIRMENT;

ADENOCARCINOMA; ADULT; AGED; CARBAZOLES; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PIPERIDINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84878347085     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70142-6     Document Type: Article

References (25)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci 2008, 105:19893-19897.
3. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009, 9:331-356.
4. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
5. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
6. Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
7. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
8. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
9. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
10. Costa DB, Kobayashi S, Pandya SS, Yeo W-L CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29:e443-e445.
11. Otterson GA, Riely GJ, Shaw AT, et al. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 7600.
12. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
13. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
14. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18:378-381.
15. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
16. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012, 118:4427-4436.
17. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89:1138-1147.
18. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
19. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-MET and ALK inhibitor, PF-02341066. Eur J Cancer 2009, 7(suppl 3):8.
20. Crinò L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 7514.
21. Xalkori (crizotinib) package insert. Initial US approval: August 2011 (revised: August 2011). Pfizer, NY, USA.
22. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation FDA, (accessed March 1, 2013). http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf.
23. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 7533.
24. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
25. Shaw AT, Kim DW, Nakagawa K, et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). European Society for Medical Oncology 2012 Sept 29-Oct 2, 2012, Vienna, Austria, abstr 2862.